AHCO vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
AHCO's Advanced Deterministic Scorecard reveals significant financial distress signals: a Piotroski F-Score of 2/9 indicates weak operational and financial health, with negative ROE (-4.25%) and declining revenue (-1.20% YoY). The absence of an Altman Z-Score raises concern about bankruptcy risk, while the Graham Number and intrinsic value are unavailable, suggesting no reliable fundamental valuation anchor. Despite a modest 1Y return of +10.2%, the stock has underperformed over 3Y (-20.2%) and 5Y (-72.3%), reflecting deep structural issues. Analysts recommend 'buy' with a target of $12.88, but this optimism is not supported by deteriorating fundamentals or consistent earnings beats.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
AHCO vs MRK: Head-to-Head Comparison
This page compares AdaptHealth Corp. (AHCO) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.